content: <HTML><HEAD>
  <TITLE>Form 8-K</TITLE>
  </HEAD>
    <BODY BGCOLOR="WHITE">
  
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="5" COLOR="#000000"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></DIV> <DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="3" COLOR="#000000"><B>WASHINGTON, D.C. 20549 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR SIZE="1" NOSHADE WIDTH="17%" COLOR="#000000"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="5" COLOR="#000000"><B>FORM 8-K </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="4" COLOR="#000000"><B>CURRENT REPORT </B></FONT></DIV> <DIV
  ALIGN="center"><FONT FACE="Times New Roman" SIZE="4" COLOR="#000000"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="4" COLOR="#000000"><B>SECURITIES EXCHANGE ACT OF 1934
  </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Date of Report (Date of earliest event reported): January 14, 2003 </B></FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="5" COLOR="#000000"><B>CONCEPTUS, INC.<U></U> </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Exact name of registrant
  as specified in charter) </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center">
  <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">
  
  <TR>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Delaware</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(State or other
  jurisdiction of</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>incorporation or organization)</B></FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>000-27596</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Commission file
  number)</B></FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>94-3170244</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(I.R.S.
  employer</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>identification no.)</B></FONT></DIV> </TD> </TR>
   </TABLE> </DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>1021 Howard Avenue </B></FONT></DIV> <DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>San Carlos, CA 94070 </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Address of principal executive offices) (Zip code) </B></FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Registrant&#146;s telephone number, including area code: (650) 802-7240 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR SIZE="1"
  NOSHADE WIDTH="17%" COLOR="#000000">
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
  
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>ITEM 5.&nbsp;&nbsp;&nbsp;&nbsp;OTHER EVENTS. </B></FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">On January 14, 2003, Conceptus, Inc. issued a press release to update on the launch of <I>Essure</I> into the U.S. market. Text of the press release follows:
  </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>SAN CARLOS, Calif. (January 14, 2003) &#151; Conceptus, Inc. (NASDAQ NM: CPTS)</B>, developer of the non-incisional permanent birth
  control procedure <I>Essure</I></FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>&#153;</SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><SUP></SUP>, today provided an update on the launch of <I>Essure</I> into the
  U.S. market. Following approval of the <I>Essure</I> system by the U.S. Food and Drug Administration (FDA) on November 4, 2002, the Company has held training sessions in several cities across the United States. The Company continues to preceptor
  newly trained physicians for approximately five cases and reports that these <I>Essure</I> procedures are being scheduled in line with company projections. To date, reimbursement claims for commercial <I>Essure</I> procedures, which commenced in
  late November, have been processed successfully and there have been no denials of coverage. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">&#147;Though we are very early in the
  process since receiving FDA approval, we are pleased with the pace of our U.S. launch and with the reception the physician and patient communities have given <I>Essure</I>,&#148; said Steve Bacich, chief executive officer. &#147;We are comfortably
  on track to have up to 700 physicians certified to perform the <I>Essure</I> procedure by the end of 2003, and we will be closely monitoring the speed at which physicians adapt their medical practices to provide <I>Essure</I> routinely to their
  patients. Importantly, from what we have experienced thus far, physicians have been reimbursed for their professional fees under various procedural codes. Based on reimbursement of procedures completed to date, we remain confident that under current
  reimbursement codes, <I>Essure</I> presents very attractive economics for physicians and payors. As with any new technology, we expect to receive questions and challenges from payors, but to date the company is not aware of any reimbursement
  challenges or denials requiring appeals from any payor organization.&#148; </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">&#147;Based on these very early indications, we currently
  feel comfortable with previous analyst estimates for 2003 sales ranging from approximately $10 million to $16 million. For 2002 sales, we estimate preliminarily that we will be at the lower end of our previous guidance of $1.6 million to $1.8
  million, although our fourth quarter and full year 2002 results are yet to be audited,&#148; added Mr. Bacich. </FONT></DIV>
   <P></P> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">2 </FONT></DIV>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
  
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Separately, the Company reported that its previously reported search for a new President and CEO is
  underway and progressing according to plan with several highly qualified candidates identified. Steven Bacich continues as chief executive officer during the interim. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT
  FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>A Need for New Permanent Birth Control </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">According to the U.S. Centers for Disease
  Control and Prevention, incisional tubal ligation continues to be the most prevalent form of birth control in the U.S, with 41 percent of women age 35-39 and 50 percent of women age 40-44 choosing incisional tubal sterilization. Incisional tubal
  ligation remains the most popular form of birth control worldwide despite the fact that it is invasive and costly. About 93 percent of the laparoscopic female sterilization procedures in the U.S. are performed in a hospital or surgi-center under
  general anesthesia, requiring four to six days before returning to regular activities. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>About </B><B><I>E<SMALL>SSURE</SMALL>
  </I></B><B></B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><I>Essure</I> deploys a soft micro-insert into the fallopian tube through the cervix using a minimally invasive
  transcervical tubal access catheter. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the fallopian tube. An <I>Essure</I> procedure does not require cutting or
  penetrating the abdomen and can be performed in a less costly procedure setting without general anesthesia. Accordingly, a woman is expected to return home about 45 minutes after the procedure is completed. </FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>About Conceptus </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Conceptus, Inc. developed
  and markets <I>Essure</I>, an innovative medical device, designed to provide a non-incisional alternative to tubal ligation, which is the leading form of birth control worldwide. The availability of <I>Essure </I>in the U.S. is expected to open up a
  market currently occupied by incisional tubal ligation and vasectomy, which combined account for over 1 million procedures annually in the United States. </FONT></DIV>
   <P></P> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">3 </FONT></DIV>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
  
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">The <I>Essure </I>procedure is based on a unique and proprietary implant and catheter delivery system
  for minimally invasive transcervical tubal access. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2"
  COLOR="#000000"><I>Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The results of product
  development program and clinical efficacy of and market demand for our product, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be
  based upon factors within the Company&#146;s control, such as strategic planning decisions by management and re-allocation of internal resources, or on factors outside of the Company&#146;s control, such as decisions by regulatory authorities,
  scientific advances by third parties and introduction of competitive products, as well as those factors set forth in the Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2001 and other filings with the Securities and
  Exchange Commission. </I></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"># # # </FONT></DIV>
   <P></P> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">4 </FONT></DIV>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
  
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>SIGNATURES </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV
  STYLE="text-indent:4%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
  authorized. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="right">
  <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">
  
  <TR>
  <TD VALIGN="top" COLSPAN="3" WIDTH="37%"> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">CONCEPTUS, INC.</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">(Registrant)</FONT></DIV> </TD> </TR>
  <TR>
  <TD HEIGHT="16"> </TD> </TR>
  <TR>
  <TD VALIGN="top" WIDTH="2%"> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">By:</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" WIDTH="37%"> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">/s/&nbsp;&nbsp;&nbsp;&nbsp;G<SMALL>LEN</SMALL> K. F<SMALL>URUTA</SMALL></FONT></DIV> <HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="37%"> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Glen K. Furuta</FONT></DIV> <DIV STYLE="margin-left:4%; text-indent:-4%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Vice&nbsp;President, Finance
  &amp; Administration</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">and Chief Financial Officer</FONT></DIV> </TD> </TR>
   </TABLE> </DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Dated: January 23, 2003 </FONT></DIV>
   <P></P> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">5 </FONT></DIV>
  
   </BODY></HTML>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "d8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 14039}]
metadata_filer: {"company-data": {"conformed-name": "CONCEPTUS INC", "cik": "0000896778", "assigned-sic": "3841", "irs-number": "973170244", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27596", "film-number": "03522820"}, "business-address": {"street1": "1021 HOWARD AVE", "city": "SAN CARLOS", "state": "CA", "zip": "94070", "phone": "4158027240"}, "mail-address": {"street1": "1021 HOWARD AVENUE", "city": "SAN CARLOS", "state": "CA", "zip": "94070"}}
text: Form 8-K
  SECURITIES AND EXCHANGE COMMISSION
  WASHINGTON, D.C. 20549
  FORM 8-K
  CURRENT REPORT
  PURSUANT TO SECTION 13 OR 15(d) OF THE
  SECURITIES EXCHANGE ACT OF 1934
  Date of Report (Date of earliest event reported): January 14, 2003
  CONCEPTUS, INC.
  (Exact name of registrant
  as specified in charter)
  Delaware
  (State or other
  jurisdiction of
  incorporation or organization)
  000-27596
  (Commission file
  number)
  94-3170244
  (I.R.S.
  employer
  identification no.)
  1021 Howard Avenue
  San Carlos, CA 94070
  (Address of principal executive offices) (Zip code)
  Registrant's telephone number, including area code: (650) 802-7240
  ITEM 5.    OTHER EVENTS.
  On January 14, 2003, Conceptus, Inc. issued a press release to update on the launch of
  Essure
  into the U.S. market. Text of the press release follows:
  SAN CARLOS, Calif. (January 14, 2003) — Conceptus, Inc. (NASDAQ NM: CPTS)
  , developer of the non-incisional permanent birth
  control procedure
  Essure
  ™
  , today provided an update on the launch of
  Essure
  into the
  U.S. market. Following approval of the
  Essure
  system by the U.S. Food and Drug Administration (FDA) on November 4, 2002, the Company has held training sessions in several cities across the United States. The Company continues to preceptor
  newly trained physicians for approximately five cases and reports that these
  Essure
  procedures are being scheduled in line with company projections. To date, reimbursement claims for commercial
  Essure
  procedures, which commenced in
  late November, have been processed successfully and there have been no denials of coverage.
  "Though we are very early in the
  process since receiving FDA approval, we are pleased with the pace of our U.S. launch and with the reception the physician and patient communities have given
  Essure
  ," said Steve Bacich, chief executive officer. "We are comfortably
  on track to have up to 700 physicians certified to perform the
  Essure
  procedure by the end of 2003, and we will be closely monitoring the speed at which physicians adapt their medical practices to provide
  Essure
  routinely to their
  patients. Importantly, from what we have experienced thus far, physicians have been reimbursed for their professional fees under various procedural codes. Based on reimbursement of procedures completed to date, we remain confident that under current
  reimbursement codes,
  Essure
  presents very attractive economics for physicians and payors. As with any new technology, we expect to receive questions and challenges from payors, but to date the company is not aware of any reimbursement
  challenges or denials requiring appeals from any payor organization."
  "Based on these very early indications, we currently
  feel comfortable with previous analyst estimates for 2003 sales ranging from approximately $10 million to $16 million. For 2002 sales, we estimate preliminarily that we will be at the lower end of our previous guidance of $1.6 million to $1.8
  million, although our fourth quarter and full year 2002 results are yet to be audited," added Mr. Bacich.
  2
  Separately, the Company reported that its previously reported search for a new President and CEO is
  underway and progressing according to plan with several highly qualified candidates identified. Steven Bacich continues as chief executive officer during the interim.
  A Need for New Permanent Birth Control
  According to the U.S. Centers for Disease
  Control and Prevention, incisional tubal ligation continues to be the most prevalent form of birth control in the U.S, with 41 percent of women age 35-39 and 50 percent of women age 40-44 choosing incisional tubal sterilization. Incisional tubal
  ligation remains the most popular form of birth control worldwide despite the fact that it is invasive and costly. About 93 percent of the laparoscopic female sterilization procedures in the U.S. are performed in a hospital or surgi-center under
  general anesthesia, requiring four to six days before returning to regular activities.
  About
  E
  SSURE
  Essure
  deploys a soft micro-insert into the fallopian tube through the cervix using a minimally invasive
  transcervical tubal access catheter. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the fallopian tube. An
  Essure
  procedure does not require cutting or
  penetrating the abdomen and can be performed in a less costly procedure setting without general anesthesia. Accordingly, a woman is expected to return home about 45 minutes after the procedure is completed.
  About Conceptus
  Conceptus, Inc. developed
  and markets
  Essure
  , an innovative medical device, designed to provide a non-incisional alternative to tubal ligation, which is the leading form of birth control worldwide. The availability of
  Essure
  in the U.S. is expected to open up a
  market currently occupied by incisional tubal ligation and vasectomy, which combined account for over 1 million procedures annually in the United States.
  3
  The
  Essure
  procedure is based on a unique and proprietary implant and catheter delivery system
  for minimally invasive transcervical tubal access.
  Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The results of product
  development program and clinical efficacy of and market demand for our product, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be
  based upon factors within the Company's control, such as strategic planning decisions by management and re-allocation of internal resources, or on factors outside of the Company's control, such as decisions by regulatory authorities,
  scientific advances by third parties and introduction of competitive products, as well as those factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2001 and other filings with the Securities and
  Exchange Commission.
  # # #
  4
  SIGNATURES
  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
  authorized.
  CONCEPTUS, INC.
  (Registrant)
  By:
  /s/    G
  LEN
  K. F
  URUTA
  Glen K. Furuta
  Vice President, Finance
  & Administration
  and Chief Financial Officer
  Dated: January 23, 2003
  5